王柏枝治疗无症状高尿酸血症肾损伤的临床经验
Wang Bozhi’s Clinical Experience in Treating Renal Injury in Asymptomatic Hyperuricemia
DOI: 10.12677/TCM.2023.123089, PDF,    科研立项经费支持
作者: 潘明奇, 黄天琪, 郝思雨:湖北中医药大学中医临床学院,湖北 武汉;邹新蓉:湖北省中医院肾病科,湖北 武汉;湖北中医药大学附属医院肾病科,湖北 武汉;湖北省中医药研究院肾病研究所,湖北 武汉
关键词: 中医药无症状高尿酸血症名医经验王柏枝Chinese Medicine Asymptomatic Hyperuricemia Famous Doctors’ Experience Wang Bozhi
摘要: 王柏枝教授作为全国名老中医肾病专家李丹初教授的学术继承人,结合从医60余年临床经验,认为无症状高尿酸血症肾损伤患者的病机为脾肾亏虚、湿浊瘀阻,以益肾祛浊、化瘀利湿为治则,运用肉桂、淫羊藿、盐杜仲、牛膝、菟丝子、黄芪、炒苍术、防己、葛根、粉萆薢、泽泻、地龙等药,拟成“降酸方”,收到良好的疗效。临诊时还应注意兼挟佐使,配合饮食控制、起居调节等,方能加速病情治愈。
Abstract: Professor Wang Bozhi, as the academic successor of Professor Li Danchu, the national famous veteran Chinese nephrologist, combined with more than 60 years of clinical experience in medicine, believes that the pathogenesis of asymptomatic hyperuricemia kidney injury patients is deficiency of spleen and kidney, stagnation of dampness and turbidity, and the treatment is to benefit the kidney and eliminate turbidity, resolve stagnation and dampness, using Cinnamon, Epimedium, salt Eucommia, Achyranthes bidentata, Cuscutae, Astragalus, Fried Atractylodes, Fourstamen Stephania Root, Pueraria Mirifica Root, powdered Dioscorea, Curcuma zedoaria, Earthworm, etc., formulated into the “acid reduction formula” received good results. In the clinic should also pay attention to both hostage and adjuvant, with dietary control, living regulation, etc., in order to accelerate the healing of the disease.
文章引用:潘明奇, 邹新蓉, 黄天琪, 郝思雨. 王柏枝治疗无症状高尿酸血症肾损伤的临床经验[J]. 中医学, 2023, 12(3): 586-591. https://doi.org/10.12677/TCM.2023.123089

参考文献

[1] 中华中医药学会风湿病分会. 痛风和高尿酸血症病证结合诊疗指南[J]. 中医杂志, 2021, 62(14): 1276-1288.
[2] Li, Q., Li, X., Wang, J., et al. (2019) Diagnosis and Treatment for Hyperuricemia and Gout: A Systematic Review of Clinical Practice Guidelines and Consensus Statements. BMJ Open, 9, e26677. [Google Scholar] [CrossRef] [PubMed]
[3] Sapankaew, T., Thadanipon, K., Ruenroengbun, N., et al. (2022) Efficacy and Safety of Urate-Lowering Agents in Asymptomatic Hyperuricemia: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. BMC Nephrology, 23, Article No. 223. [Google Scholar] [CrossRef] [PubMed]
[4] Zhang, L., An, K., Mou, X., et al. (2022) Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients with Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 12, Article ID: 795082. [Google Scholar] [CrossRef] [PubMed]
[5] Yang, L., Wang, B., Ma, L., et al. (2022) Traditional Chinese Herbs and Natural Products in Hyperuricemia-Induced Chronic Kidney Disease. Frontiers in Pharmacology, 13, Article ID: 971032. [Google Scholar] [CrossRef] [PubMed]
[6] Maiuolo, J., Oppedisano, F., Gratteri, S., et al. (2016) Regulation of Uric Acid Metabolism and Excretion. International Journal of Cardiology, 213, 8-14. [Google Scholar] [CrossRef] [PubMed]
[7] Narang, R.K. and Dalbeth, N. (2020) Pathophysiology of Gout. Seminars in Nephrology, 40, 550-563. [Google Scholar] [CrossRef] [PubMed]
[8] Xu, L., Shi, Y., Zhuang, S., et al. (2017) Recent Advances on Uric Acid Transporters. Oncotarget, 8, 100852-100862. [Google Scholar] [CrossRef] [PubMed]
[9] Le, M.T., Shafiu, M., Mu, W., et al. (2008) SLC2A9—A Fructose Transporter Identified as a Novel Uric Acid Transporter. Nephrology Dialysis Transplantation, 23, 2746-2749. [Google Scholar] [CrossRef] [PubMed]
[10] Dehghan, A., Köttgen, A., Yang, Q., et al. (2008) Association of Three Genetic Loci with Uric Acid Concentration and Risk of Gout: A Genome-Wide Association Study. The Lancet, 372, 1953-1961. [Google Scholar] [CrossRef
[11] Wang, H., Zhang, H., Sun, L., et al. (2018) Roles of Hyperuricemia in Metabolic Syndrome and Cardiac-Kidney-Vascular System Diseases. The American Journal of Translational Research, 10, 2749-2763.
[12] Komori, H., Yamada, K. and Tamai, I. (2018) Hyperuricemia Enhances Intracellular Urate Accumulation via Down-Regulation of Cell-Surface BCRP/ABCG2 Expression in Vascular Endothelial Cells. Biochimica et Biophysica Acta—Biomembranes, 1860, 973-980. [Google Scholar] [CrossRef] [PubMed]
[13] Mallat, S.G., Al, K.S., Tanios, B.Y., et al. (2016) Hyperuricemia, Hypertension, and Chronic Kidney Disease: An Emerging Association. Current Hypertension Reports, 18, 74. [Google Scholar] [CrossRef] [PubMed]
[14] Su, H., Yang, C., Liang, D., et al. (2020) Research Advances in the Mechanisms of Hyperuricemia-Induced Renal Injury. BioMed Research International, 2020, Article ID: 5817348. [Google Scholar] [CrossRef] [PubMed]
[15] Khanna, D., Fitzgerald, J.D., Khanna, P.P., et al. (2012) 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care & Research (Hoboken), 64, 1431-1446. [Google Scholar] [CrossRef] [PubMed]
[16] Khanna, D., Khanna, P.P., Fitzgerald, J.D., et al. (2012) 2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and Antiinflammatory Prophylaxis of Acute Gouty Arthritis. Arthritis Care & Research (Hoboken), 64, 1447-1461. [Google Scholar] [CrossRef] [PubMed]
[17] Becker, M.A., Kisicki, J., Khosravan, R., et al. (2004) Febuxostat (TMX-67), a Novel, Non-Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers. Nucleosides Nucleotides Nucleic Acids, 23, 1111-1116. [Google Scholar] [CrossRef
[18] Zennaro, C., Tonon, F., Zarattini, P., et al. (2017) The Renal Phenotype of Allopurinol-Treated HPRT-Deficient Mouse. PLOS ONE, 12, e173512. [Google Scholar] [CrossRef] [PubMed]
[19] Chen, C., Lü, J. and Yao, Q. (2016) Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. Medical Science Monitor, 22, 2501-2512. [Google Scholar] [CrossRef
[20] White, W.B., Saag, K.G., Becker, M.A., et al. (2018) Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England Journal of Medicine, 378, 1200-1210. [Google Scholar] [CrossRef
[21] Jordan, A. and Gresser, U. (2018) Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat. Pharmaceuticals (Basel), 11, 51. [Google Scholar] [CrossRef] [PubMed]
[22] 倪青. 高尿酸血症和痛风病证结合诊疗指南(2021-01-20) [J]. 世界中医药, 2021, 16(2): 183-189.
[23] Kimura, K., Hosoya, T., Uchida, S., et al. (2018) Febuxostat Therapy for Patients with Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. American Journal of Kidney Diseases, 72, 798-810. [Google Scholar] [CrossRef] [PubMed]
[24] Kim, A., Kim, Y., Kim, G., et al. (2020) Comparison of Persistence Rates between Allopurinol and Febuxostat as First-Line Urate-Lowering Therapy in Patients with Gout: An 8-Year Retrospective Cohort Study. Clinical Rheumatology, 39, 3769-3776. [Google Scholar] [CrossRef] [PubMed]